{"id":68331,"date":"2026-06-16T22:16:24","date_gmt":"2026-06-16T14:16:24","guid":{"rendered":"https:\/\/flcube.com\/?p=68331"},"modified":"2026-06-16T22:16:26","modified_gmt":"2026-06-16T14:16:26","slug":"chia-tai-tianqing-presents-positive-phase-ii-data-for-tqc2938-in-allergic-rhinitis-novel-st2-targeting-mab-shows-efficacy-across-inflammatory-pathways","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68331","title":{"rendered":"Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis \u2013 Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ)<\/strong>, a subsidiary of <strong>Sino Biopharmaceutical Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>), announced <strong>Phase II clinical trial results<\/strong> for <strong>TQC2938<\/strong>, a Class 1 innovative drug independently developed by the company, at the <strong>2026 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress<\/strong>. The study evaluated the humanized IgG2 monoclonal antibody targeting ST2 in patients with <strong>moderate-to-severe seasonal allergic rhinitis (SAR)<\/strong>, demonstrating promising efficacy and safety profiles.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-overview\" class=\"wp-block-heading\">Clinical Trial Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Conference<\/strong><\/td><td>2026 EAACI Annual Congress<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>TQC2938 \u2013 humanized IgG2 monoclonal antibody targeting ST2<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ)<\/td><\/tr><tr><td><strong>Parent Company<\/strong><\/td><td>Sino Biopharmaceutical Limited (HKG: 1177)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Moderate-to-severe seasonal allergic rhinitis (SAR)<\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>Phase II, randomized, placebo-controlled<\/td><\/tr><tr><td><strong>Dose Groups<\/strong><\/td><td>210 mg, 420 mg, 630 mg<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-mechanism-of-action-amp-innovation\" class=\"wp-block-heading\">Mechanism of Action &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> ST2 protein \u2013 receptor for interleukin-33 (IL-33)<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Specifically binds to human ST2, blocking IL-33 interaction<\/li>\n\n\n\n<li><strong>Therapeutic Advantage:<\/strong> Simultaneously inhibits both type 2 and non-type 2 inflammatory pathways involved in SAR pathogenesis<\/li>\n\n\n\n<li><strong>Classification:<\/strong> Class 1 innovative drug (first-in-class in China)<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Novel approach addressing broader inflammatory spectrum compared to existing SAR therapies focused primarily on type 2 inflammation<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-primary-endpoint-results-rtnss-improvement\" class=\"wp-block-heading\">Primary Endpoint Results \u2013 rTNSS Improvement<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Time Point<\/th><th>420 mg Dose vs Placebo<\/th><th>p-value<\/th><th>Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>2 Weeks<\/strong><\/td><td>-0.97 point improvement<\/td><td>0.1166<\/td><td>Not statistically significant<\/td><\/tr><tr><td><strong>4 Weeks<\/strong><\/td><td>-1.37 point improvement<\/td><td>0.0342<\/td><td>Statistically significant<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>420 mg dose group<\/strong> demonstrated the most pronounced overall efficacy among all dose groups tested, with statistically significant improvement in reflective Total Nasal Symptom Score (rTNSS) at 4 weeks.<\/p>\n\n\n\n<h2 id=\"h-secondary-endpoint-results\" class=\"wp-block-heading\">Secondary Endpoint Results<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The 420 mg dose group showed <strong>statistically significant improvements across all key secondary endpoints<\/strong> compared to placebo:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>rTNSS at 4 weeks:<\/strong> Significant improvement (p=0.0342)<\/li>\n\n\n\n<li><strong>rTOSS (reflective Total Ocular Symptom Score) at 2 weeks:<\/strong> Significant improvement<\/li>\n\n\n\n<li><strong>rTOSS at 4 weeks:<\/strong> Significant improvement<\/li>\n\n\n\n<li><strong>RQLQ (Rhinoconjunctivitis Quality of Life Questionnaire) at 2 weeks:<\/strong> Significant improvement<\/li>\n\n\n\n<li><strong>RQLQ at 4 weeks:<\/strong> Significant improvement<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">These comprehensive results demonstrate TQC2938&#8217;s ability to improve both nasal and ocular symptoms while enhancing patients&#8217; quality of life.<\/p>\n\n\n\n<h2 id=\"h-safety-profile\" class=\"wp-block-heading\">Safety Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Adverse Event Rate:<\/strong> 420 mg dose group showed favorable safety profile<\/li>\n\n\n\n<li><strong>Comparison to Placebo:<\/strong> Overall adverse event rate comparable to placebo group<\/li>\n\n\n\n<li><strong>Tolerability:<\/strong> No dose-limiting toxicities observed in the 420 mg cohort<\/li>\n\n\n\n<li><strong>Safety Conclusion:<\/strong> Well-tolerated with no significant safety concerns identified<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-significance\" class=\"wp-block-heading\">Market Impact &amp; Strategic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SAR Market Opportunity:<\/strong> Global allergic rhinitis therapeutics market projected to reach <strong>USD 12.5 billion by 2028<\/strong>, with significant unmet need in moderate-to-severe cases<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Current SAR treatments include antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists; TQC2938 represents a novel biologic approach<\/li>\n\n\n\n<li><strong>Therapeutic Gap:<\/strong> Existing biologics for allergic conditions primarily target type 2 inflammation; TQC2938&#8217;s dual pathway inhibition could address broader patient populations<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> If approved, TQC2938 would be among the first ST2-targeting biologics globally for allergic rhinitis, positioning Chia Tai Tianqing as an innovator in immunology<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The positive Phase II data support advancement to Phase III development, with the 420 mg dose identified as the optimal dose for further clinical evaluation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and commercial expectations for TQC2938. Actual results may differ due to risks including Phase III trial outcomes, regulatory decisions, competitive dynamics, and execution of Chia Tai Tianqing&#8217;s development strategy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061600038_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026061600038_c.\"><\/object><a id=\"wp-block-file--media-f6e9215d-9e6c-462b-beb7-53a40a91252e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061600038_c.pdf\">2026061600038_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061600038_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-f6e9215d-9e6c-462b-beb7-53a40a91252e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited (HKG:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[106,661,17,908,313],"class_list":["post-68331","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-academic-conference","tag-chia-tai-tianqing-pharmaceutical","tag-clinical-trial-results","tag-hkg-1177","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis \u2013 Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), announced Phase II clinical trial results for TQC2938, a Class 1 innovative drug independently developed by the company, at the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. The study evaluated the humanized IgG2 monoclonal antibody targeting ST2 in patients with moderate-to-severe seasonal allergic rhinitis (SAR), demonstrating promising efficacy and safety profiles.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68331\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis \u2013 Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), announced Phase II clinical trial results for TQC2938, a Class 1 innovative drug independently developed by the company, at the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. The study evaluated the humanized IgG2 monoclonal antibody targeting ST2 in patients with moderate-to-severe seasonal allergic rhinitis (SAR), demonstrating promising efficacy and safety profiles.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68331\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-16T14:16:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-16T14:16:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68331#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68331\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis \u2013 Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways\",\"datePublished\":\"2026-06-16T14:16:24+00:00\",\"dateModified\":\"2026-06-16T14:16:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68331\"},\"wordCount\":534,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Academic conference\",\"Chia Tai Tianqing Pharmaceutical\",\"Clinical trial results\",\"HKG: 1177\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68331#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68331\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68331\",\"name\":\"Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis \u2013 Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-16T14:16:24+00:00\",\"dateModified\":\"2026-06-16T14:16:26+00:00\",\"description\":\"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), announced Phase II clinical trial results for TQC2938, a Class 1 innovative drug independently developed by the company, at the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. The study evaluated the humanized IgG2 monoclonal antibody targeting ST2 in patients with moderate-to-severe seasonal allergic rhinitis (SAR), demonstrating promising efficacy and safety profiles.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68331#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68331\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68331#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis \u2013 Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis \u2013 Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), announced Phase II clinical trial results for TQC2938, a Class 1 innovative drug independently developed by the company, at the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. The study evaluated the humanized IgG2 monoclonal antibody targeting ST2 in patients with moderate-to-severe seasonal allergic rhinitis (SAR), demonstrating promising efficacy and safety profiles.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68331","og_locale":"en_US","og_type":"article","og_title":"Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis \u2013 Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways","og_description":"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), announced Phase II clinical trial results for TQC2938, a Class 1 innovative drug independently developed by the company, at the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. The study evaluated the humanized IgG2 monoclonal antibody targeting ST2 in patients with moderate-to-severe seasonal allergic rhinitis (SAR), demonstrating promising efficacy and safety profiles.","og_url":"https:\/\/flcube.com\/?p=68331","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-16T14:16:24+00:00","article_modified_time":"2026-06-16T14:16:26+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68331#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68331"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis \u2013 Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways","datePublished":"2026-06-16T14:16:24+00:00","dateModified":"2026-06-16T14:16:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68331"},"wordCount":534,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Academic conference","Chia Tai Tianqing Pharmaceutical","Clinical trial results","HKG: 1177","Sino Biopharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68331#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68331","url":"https:\/\/flcube.com\/?p=68331","name":"Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis \u2013 Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-16T14:16:24+00:00","dateModified":"2026-06-16T14:16:26+00:00","description":"Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), announced Phase II clinical trial results for TQC2938, a Class 1 innovative drug independently developed by the company, at the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. The study evaluated the humanized IgG2 monoclonal antibody targeting ST2 in patients with moderate-to-severe seasonal allergic rhinitis (SAR), demonstrating promising efficacy and safety profiles.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68331#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68331"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68331#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis \u2013 Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68331"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68331\/revisions"}],"predecessor-version":[{"id":68338,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68331\/revisions\/68338"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68331"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68331"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}